Today, we presented preclinical data of our experimental candidate, demonstrating inflammation resolution and tissue repair in models of chronic inflammatory conditions at the 2024 American College of Rheumatology (ACR) Annual Meeting. To learn more about the exciting findings, read the full press release here: https://bit.ly/3YYKkRd #ACR24?
关于我们
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
- 网站
-
https://www.nektar.com
Nektar Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 501-1,000 人
- 总部
- San Francisco，California
- 类型
- 上市公司
- 创立
- 1990
- 领域
- Drug Development和Polymer Conjugate Chemistry
地点
动态
-
Today, Nektar and collaborators presented data from a Phase 2 trial for treating radiation induced lymphopenia in locally advanced NSCLC patients after chemoradiation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. To learn more, read the full press release here:?https://bit.ly/4fgbqu1 #SITC2024 #SITC24 #Oncology #CancerResearch
-
-
Today, we announced the sale of our PEGylation reagent manufacturing facility in Huntsville, AL, to Ampersand Capital Partners. We look forward to the site’s future growth as a standalone manufacturing business dedicated to serving existing and future customers. See more here: https://bit.ly/3AsKFDk
-
-
Excited to share our recent publication in?Nature Portfolio showcasing data from multiple Phase1b studies highlighting the efficacy, safety, and tolerability of our experimental drug in patients with two inflammatory skin diseases. Read the full publication here:?https://bit.ly/3C2SGiN
-
We're proud to be a sponsor of this year's NAAF Conference. Watch this 2024 Conference Highlight Video which captures some of the spirit, excitement, and emotion of this year's conference.
Watch this 2024 Conference Highlight Video which captures some of the spirit, excitement, and emotion of that unforgettable experience. https://lnkd.in/dTX3r2uV We can’t wait to see you in Chicago next June!
NAAF Conference - National Alopecia Areata Foundation | NAAF
https://www.naaf.org
-
Did you know that more than 31 million people in the U.S. have #eczema? Focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases, Nektar is advancing our lead pipeline candidate, REZPEG, in a Phase 2b study for the treatment of #atopicdermatitis: https://bit.ly/48e4NF2 #EczemaAwarenessMonth
-
-
We announced the publication of clinical data in Blood from our Phase 1 study evaluating NKTR-255 in combination with CD19/22 CAR-T cell therapy, showing favorable efficacy, in relapsed or refractory B-cell Acute Lymphoblastic #Leukemia. More details and access to the full article: https://bit.ly/407Hzis
-
-
At #EADV2024, Nektar is presenting?three posters, including one poster featuring new biomarker analysis data of REZPEG, our novel first-in-class Treg cell stimulator, currently being evaluated in two Phase 2b studies in #atopicdermatitis and #alopeciaareata. Learn more: https://bit.ly/3MZOnaj? ?
-
-
Nearly 2% of people across the world will experience #alopeciaareata at some point in their lifetime. We’re proud to be evaluating our lead program, REZPEG, in a Phase 2b study for the treatment of alopecia areata and other #autoimmunedisorders. Learn more: https://bit.ly/48e4NF2 #AlopeciaAreataAwarenessMonth
-
-
It’s #AtopicEczemaDay. Dedicated to developing novel therapies for patients affected by #autoimmunedisorders, Nektar is evaluating our novel regulatory T-cell selective IL-2 conjugate, REZPEG, for potential treatment of inflammatory skin diseases, including #atopicdermatitis. Learn more: https://bit.ly/48e4NF2
-